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COmmunity-based Rehabilitation after
Knee Arthroplasty (CORKA): study protocol
for a randomised controlled trial
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Gary Collins5, Susan Dutton5, Helen Campbell6, Nicola Kenealy1, Jon Room1,2 and Sarah E. Lamb1
Abstract
Background: The number of knee arthroplasties performed each year is steadily increasing. Although the outcome
is generally favourable, up to 15 % fail to achieve a satisfactory clinical outcome which may indicate that the
existing model of rehabilitation after surgery may not be the most efficacious. Given the increasing number of
knee arthroplasties, the relative limited physiotherapy resources available and the increasing age and frailty of
patients receiving arthroplasty surgery, it is important that we concentrate our rehabilitation resources on those
patients who most need help to achieve a good outcome. This pragmatic randomised controlled trial will
investigate the clinical and cost-effectiveness of a community-based multidisciplinary rehabilitation intervention
in comparison to usual care.
Methods/design: The trial is designed as a prospective, single-blind, two-arm randomised controlled trial (RCT).
A bespoke algorithm to predict which patients are at risk of poor outcome will be developed to screen patients
for inclusion into a RCT using existing datasets. Six hundred and twenty patients undergoing knee arthroplasty,
and assessed as being at risk of poor outcome using this algorithm, will be recruited and randomly allocated
to one of two rehabilitation strategies: usual care or an individually tailored community-based rehabilitation package.
The primary outcome is the Late Life Function and Disability Instrument measured at 1 year after surgery. Secondary
outcomes include the Oxford Knee Score, the Knee injury and Osteoarthritis Outcome Score quality of life subscale, the
Physical Activity Scale for the Elderly, the EQ-5D-5L and physical function measured by three performance-based tests:
figure of eight, sit to stand and single-leg stand. A nested qualitative study will explore patient experience and
perceptions and a health economic analysis will assess whether a home-based multidisciplinary individually
tailored rehabilitation package represents good value for money when compared to usual care.
Discussion: There is lack of consensus about what constitutes the optimum package of rehabilitation after knee
arthroplasty surgery. There is also a need to tailor rehabilitation to the needs of those predicted to do least well
by focussing on interventions that target the elderly and frailer population receiving arthroplasty surgery.
Trial registration: ISRCTN 13517704, registered on 12 February 2015.
Keywords: Randomised controlled trial, Knee arthroplasty, Physiotherapy, Occupational therapy, Rehabilitation,
Community, Elderly, Frail
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Background
The number of knee arthroplasty (KA) operations taking
place in the UK is continuing to rise; 96,986 primary
KAs were recorded in 2014, a 12.9 % increase over 2013
with osteoarthritis the most common indication for
surgery [1]. Large numbers of KAs are being performed
in older and frailer patients. In 2014, 18 % of operations
were performed on patients with a patient physical sta-
tus recorded as ‘incapacitating systemic disease’ (P3 or
greater), with the 99th percentile age being between 85
and 88 years and the oldest patient being 101 years [1].
The existing literature demonstrates that predicting
who will do well after KA is a complex construct and
not determined by simplistic linear relationships with
factors such as age or presurgical function. A number
of studies have investigated the influence of preopera-
tive predictors on postoperative outcome of KA. How-
ever, no screening algorithm that can accurately
identify and predict who is at a risk of poor postopera-
tive outcome associated with rehabilitation is currently
in existence. Generally, patients who are better pre-
operatively tend to have a better postoperative outcome
[2–5]. Evidence on the influence of comorbidities on
postoperative outcome is inconclusive. A number of
studies demonstrate the association of preoperative co-
morbidities with a worse postoperative outcome [4, 6,
7] but others do not observe such an association [3, 8].
Age, however, should not be a barrier to having a good
outcome from KA, with reports of a successful out-
come in patients aged over 80 years [9].
Furthermore, it is known that outcome following KA
is multifaceted; around 15 % of patients do not report a
good outcome following their KA and have continuing
pain and mobility problems which limit or prevent them
from doing activities they would like to do after surgery
[10]. Factors such as the amount of pain and limitation
of balance and muscle strength may contribute to poorer
outcome [11] and effective rehabilitation interventions
may contribute to optimising postoperative return to
functional activities [12].
Rehabilitation approaches
Systematic reviews evaluating the effectiveness of exer-
cise support the use of functional physiotherapy exercise
interventions following discharge to obtain short-term
benefit following elective primary KA [12, 13]. These
reviews revealed the complexity involved in deciding
the best rehabilitation after KA. The lack of knowledge
regarding current physiotherapy practice has been
recognised internationally [14], with no generally ac-
cepted rehabilitation protocol for patients post KA. A
recent review examined multidisciplinary rehabilitation
programmes following hip and knee joint arthroplasty
and, although it concluded that home-based care may
be beneficial, stressed the low quality of the current evi-
dence base and concluded that further high-quality re-
search is needed [15]. Moreover, there are no published
randomised controlled trials (RCTs) of occupational
therapy after KA and many published studies either
have serious methodological limitations or it is difficult
to extrapolate the contribution of occupational therapy
from the overall rehabilitation package.
In the UK, Clinical Commissioning Groups typically
will fund four to six sessions of outpatient postopera-
tive physiotherapy [16], however, previous research has
shown that this short course of physiotherapy is not
needed by all patients to help them recover after sur-
gery [17]. Conversely, concern has been raised that
many exercise programmes lack adequate intensity to
lead to optimal recovery [18, 19]. Internationally, where
much greater doses of physiotherapy are often pro-
vided, research indicates that 12–18 h of physiotherapy
[20], or a mean of 17 visits [21], may be needed to pro-
duce benefit. These levels of care may be well beyond
those provided in the UK and, in the current economic
climate, may be more than the NHS can afford given
the numbers of KAs undertaken each year. Given the
increasing number of KAs, the relatively limited physio-
therapy resources available and the increasing age and
frailty of patients receiving joint arthroplasty, it is import-
ant that we concentrate our rehabilitation resources on
those patients who need most help to avoid a poor
outcome.
Current evidence suggests an optimal rehabilitation
approach should include a structured programme that
incorporates muscle-strengthening exercises, including
resistive muscle-strengthening exercises which are regu-
larly progressed along with exercises to improve balance.
Exercises which facilitate an improvement or maintenance
of daily living activities, such as housework and personal
care activities, plus endurance exercises to improve base-
line levels of physical activity are also required as overall
health permits [22–25]. It is also imperative that exercise
and functional rehabilitation are linked to demonstrable
increases in activity output and participation levels.
Many patients may also benefit from environmental
modifications, aids and appliances where impairments
cannot be overcome or as part of the therapeutic
programme to increase their functional performance;
these will be provided where needed as part of the inter-
vention. Our approach is to include exercises and activ-
ities which address more than one aim, are progressed
in difficulty and are individually tailored to each patient
to maximise their performance. The intervention in this
study also needs to be manageable for older patients,
who may be frail and with significant comorbidities and
for whom the 60–90-min intensive sessions recom-
mended following total KA [23] are unachievable.
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The programme must also be attentive to the need to de-
velop an intervention that can translate into routine clinical
practice and be affordable to health care commissioners.
In view of this we will develop an intervention that is
staffed by both qualified physiotherapists and rehabilita-
tion assistants. Rehabilitation assistants are routinely
used in the delivery of exercise programmes to patients
following orthopaedic surgery and we will test the safety
and efficacy of this model of delivery.
We have selected to test a combined physiotherapy- and
occupational therapy-informed intervention delivered in
patients’ homes. The full details of the intervention will be
published separately in accordance with recent TIDieR
guidance [26].
Objectives
1. To design a prognostic screening algorithm which
will be developed based on an analysis of factors
associated with poor outcome following KA
2. To evaluate, in a population identified as at risk
of poor outcome, if a multicomponent rehabilitation
programme delivered in patients’ homes can
improve their outcome compared to those receiving
the standard outpatient rehabilitation over a
12-month period
3. To undertake a nested qualitative study exploring
the perceptions of both patients and clinicians on
the use of the community-based rehabilitation
programme
4. To undertake an economic analysis to compare
the cost-effectiveness of both the intervention and
usual care
Methods/design
Trial design
COmmunity-based Rehabilitation after Knee Arthroplasty
(CORKA) is a prospective, individually randomised
controlled trial with blinded outcome assessment for
the clinical outcomes at baseline, 6 and 12 months. It
will also include a nested qualitative study and a health
economic analysis. The trial was preceded by a develop-
ment phase where we designed a screening tool by ana-
lysing data from existing NHS datasets from the KAT
trial [27] to develop an algorithm to be used at pre-
operative assessment to identify patients likely to be at
risk of poor outcome after KA. The screening tool was
developed and internally validated prior to the recruit-
ment of the first patient into the trial. A manuscript
describing the development and internal validation of
the screening tool is currently being prepared for
submission.
Patients will be randomised to either usual care (control)
or to a community-based intervention group. Baseline
assessments will be collected no more than 4 weeks be-
fore participants’ date of surgery. Follow-up assessment
will take place at 6 and 12 months after randomisation.
The protocol conforms to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines for nonpharmacological studies [28] (Fig. 1).
Study population
Six hundred and twenty patients at risk of poor outcome,
identified through the screening algorithm will be re-
cruited to the study. The planned recruitment period is
18 months.
Eligibility criteria
Inclusion criteria
 Participant is willing and able to give informed
consent for participation in the study
 Men or women, aged 55 years or above
 Primary unilateral KA as a scheduled procedure
 At risk of poor outcome – as identified by the
study screening tool
 Willing to allow rehabilitation teams to attend their
home to deliver the community-based rehabilitation
programme if randomised to the intervention arm
Exclusion criteria
 Any absolute contraindications to exercise
 Severe cardiovascular or pulmonary disease
(New York Heart Association classes III–IV)
 Severe dementia, assessed using the hospital
dementia screening tool
 Rheumatoid arthritis (active disease)
 Further lower limb arthroplasty surgery planned
within 12 months.
 Serious perioperative complications
Procedures
Recruitment
A minimum of six and up to ten NHS hospitals that
carry out elective primary KA will participate to recruit
620 participants. People who are scheduled to receive a
knee replacement will be invited to take part in the trial
once they have been be assessed for likelihood of poor
outcome using the screening tool developed as part of
this study. This will be administered in the preoperative
assessment clinic and the data will be screened for study
suitability by a member of the local team. Baseline
assessments will be collected no longer than 4 weeks be-
fore participants’ date of surgery. Follow-up assessment
will take place at 6 and 12 months after randomisation.
Randomisation, blinding and allocation concealment
The final decision about inclusion and recruitment to
the trial will be made at day 3 post operatively, when
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patients may be excluded if they have had any serious
perioperative complications; or on discharge from hos-
pital if before day 3.
If eligible, participants will have their consent con-
firmed and randomisation will take place using a
website-based system provided by the Oxford Clinical
Trials Research Unit randomisation service. Randomisa-
tion uses permuted blocks of random and undisclosed
sizes stratified by site. Participants will be allocated to
receive one of two rehabilitation options, either ‘usual
care’ or the ‘home-based exercise programme’. The re-
search therapist at each site will then be informed of
the participant’s treatment allocation and will liaise
with the appropriate clinical staff to provide the correct
intervention.
Due to the nature of the intervention participants and
those delivering the rehabilitation will be aware of the
treatment allocation; by virtue of the design it is not
possible to blind the participants or physiotherapists [29].
Follow-up assessments will be performed by a
blinded research physiotherapist and the staff recruit-
ing participants and performing baseline and follow-
up assessments will not be involved in delivering the
treatment interventions. All data will be entered by a
data entry assistant to ensure that the research physio-
therapists remain blind to treatment allocation. All
outcome assessors will remain blinded until the final
analysis is complete. We will use the methods de-
scribed by Minns Lowe et al. to assess the success of
assessor blinding [29].
Outcome measures
Primary outcome measure
The Late Life Function and Disability Instrument (LLFDI)
is the primary outcome assessment. It is a 48-item out-
come instrument developed and validated specifically
for community-dwelling older adults, which assesses
and responds to meaningful change in two distinct do-
mains: function; a person’s ability to do discrete actions
or activities, and disability; and a person’s performance of
socially defined life tasks [30, 31]. The LLFDI will be re-
ported by the aggregated function and disability compo-
nent scores as well as a whole to correspond to the
International classification of functioning, disability and
health (ICF). The total score will be the primary outcome.
Secondary outcome measures
The Oxford Knee Score (OKS). This is a disease-specific
measure to assess function and to allow comparison
with data from large epidemiological cohort studies. It is
a 12-item patient-reported outcome measure which
measures pain and function after KA surgery [32].
The Knee injury and Osteoarthritis Outcome Score
(KOOS) quality of life subscale. The KOOS is a specific-
ally validated instrument developed for knee osteoarth-
ritis, which can also be analysed to calculate a Western
Ontario and McMaster Universities (WOMAC) Index. It
is a self-reported questionnaire consisting of five sub-
scales: pain, other symptoms, activities of daily living
Fig. 1 Study flow chart
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(ADL), function in sport and recreation (sport/rec) and
knee-related quality of life (QOL). The quality of life
subscale of the KOOS, consists of four self-reported
questions [33].
The Physical Activity Scale for the Elderly (PASE)
questionnaire. A self-reported scale designed to measure
the physical activity level of those aged 65 years and
older. It consists of three subscales, leisure time activity,
household activity and work-related activity. This is a
short, self-administered questionnaire to assess activity
in the past week [34].
Health economics using the EuroQol 5 dimensions, 5
levels questionnaire (EQ-5D-5L). A validated self-reported
outcome measure consisting of five dimensions: mo-
bility, self-care, usual activity, pain and discomfort and
anxiety and depression. Each dimension has five cat-
egories of response. It is designed to provide a generic
measure of health status for clinical and/or economic
evaluation [35].
Functional Co-morbidities Index. This will be completed
as other diseases are likely to be present in this older
population which might affect physical outcomes [36].
Physical measures. Measures of outcome include mea-
sures of balance, mobility and physical activity, all areas af-
fected by KA. Each test is reliable and valid, has been used
with older, community-dwelling adults and has been
shown to be responsive in previous rehabilitation studies.
Physical function will be measured by three physical per-
formance tasks: the Figure of 8 walk test, the 30-s chair-
stand test and the single-leg stance. [37–39].
All data will be collected by face-to-face clinical
assessment at baseline and 6 and 12 months post ran-
domisation [Table 1].
Interventions
Usual care arm
Those in the usual care arm will receive the routine
care offered by the local centre. This is likely to
Table 1 Summary of outcomes and assessment schedule
Time point Enrolment/
Pre op clinic
Baseline Surgery Allocation Post surgery
Weeks
0–2
Weeks
3–6
6 months 12 months
KA surgery X
High-risk screening tool applied X
Eligibility screen: inclusion/exclusion criteria X
Informed consent X
Baseline questionnaire X
Randomisation X
Intervention arm: home-based exercise programme X
Usual care arm: routine care, local centre X
Assessments
• Demographics
• Medical History
• EQ-5D-5L presurgery recall
X
X
X
• LLFDI score
• Oxford Knee Score
• Quality of life subscale of the Knee Osteoarthritis
Outcome Score (KOOS)
• Physical Activity Scale for the Elderly (PASE)
questionnaire.
• Health economics using the EQ-5D-5L
• 30-s chair-stand test
• Figure of 8 walk test
• Single-leg stance
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Participant Diary: completed daily/as required
at home for 6 weeks
Then weekly recording:
• Exercises undertaken
• Medication taken
• Use of health care services and personnel
X X X X
Adverse events
Collected throughout
X X X X X
This table excludes the qualitative substudy taking place in selected sites/participants
EQ-5D-5L EuroQol 5 dimensions, 5 levels questionnaire, KA knee arthroplasty, LLFDI Late Life Function and Disability Instrument
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include written advice on home exercises provided on
discharge from hospital; between 1 and 6 sessions of
traditional outpatient physiotherapy and home re-
quirements assessed by an occupational therapist to
identify barriers to discharge. It is recognised that
usual care can vary geographically [16] and this may
include the number of sessions of physiotherapy given
post discharge. To standardise the usual care arm, as
far as possible there will be a minimum and maximum
number of session that will be included in usual care.
Participants will be expected to attend at least one ses-
sion of outpatient physiotherapy and no more than six
sessions.
Intervention arm
The intervention is a multicomponent rehabilitation
programme designed to improve both the function of
‘at risk’ patients and their participation in activities.
The largest component will be an exercise programme,
delivered in the participants’ own homes, in order to
make it accessible to those without good social support or
those with physical or mental frailty. The programme will
consist of an individualised set of exercises covering exer-
cises selected from a menu to include at least one exercise
from each of the following sections: knee flexion, knee
extension, knee-strengthening, hip-strengthening, static
balance and gait skills. Attention will also be paid to
pain management, confidence-building, appropriate
provision of aids and equipment and suitability of the
home environment. In order to make the intervention
affordable to the NHS, the trial will use a combination
of qualified physiotherapists, occupational therapists
and rehabilitation assistants to deliver the intervention.
The programme will focus on both improving func-
tional outcome but also on participation levels.
Collaborating sites will provide the CORKA home-
based rehabilitation programme. It will commence deliv-
ery within 4 weeks of KA surgery. (A window of 2–8
weeks for starting the intervention will be allowed before
a protocol deviation is considered to have occurred.)
Governance
The sponsor of the trial is the University of Oxford and
the University’s Clinical Trials and Research Office
(CTRG) will oversee the roles and responsibilities dele-
gated to them as research sponsor.
Trial Steering Committee (TSC): the TSC, which in-
cludes independent members, provides overall super-
vision of the trial on behalf of the funder. The terms
of reference are agreed with the Health Technology
Assessment (HTA) and drawn up in a TSC charter
which outlines its roles and responsibilities. Meetings
of the TSC will take place at least once a year during
the recruitment period.
Trial Management Group (TMG): the TMG is made
up of the investigators listed on the front of this proto-
col, and staff working on the project within the Oxford
Clinical Trials Research Unit (OCTRU)/CCTR Trials
Group. This group will oversee the day-to-day running
of the trial and will meet regularly throughout the life-
time of the study.
Data Monitoring and Safety Committee (DMSC): the
DMSC is a group of independent experts external to the
trial who assess the progress, conduct, participant safety
and, if required, critical endpoints of a clinical trial. The
DMSC will adopt a DAMOCLES charter which defines
its terms of reference and operation in relation to trial
oversight [40]. It will not be asked to perform any formal
interim analyses of effectiveness. It will, however, see
copies of data accrued to date, or summaries of that
data by treatment group and will assess the screening
algorithm against the eligibility criteria. It will also
consider emerging evidence from other related trials
or research and review-related serious adverse events
(SAEs) that have been reported. It may also advise the
chair of the TSC at any time if, in its view, the trial
should be stopped for ethical reasons, including con-
cerns about participant safety. DMSC meetings will be
held at least annually during the recruitment phase of
the study.
All data and documentation will be stored in accord-
ance with regulatory requirements regarding confidenti-
ality and access to the data will be restricted to
authorised trial personnel. The Oxford Clinical Trials
Research Unit will securely hold the database.
Reporting of adverse events
Full definitions of SAEs, foreseeable adverse events and
the mechanisms for reporting and assessing adverse
events are given in the full protocol available on line. A
SAE is any untoward medical occurrence that: (1) re-
sults in death, (2) is life-threatening, (3) requires in-
patient hospitalisation or prolongation of existing
hospitalisation, (4) results in persistent or significant
disability/incapacity or (5) consists of a congenital
anomaly or birth defect. Other ‘important medical
events’ may also be considered serious if they jeopard-
ise the participant or require an intervention to prevent
one of the above consequences.
Foreseeable adverse events
Fall risk is an important issue as this population is at
higher risk for falls; whether the home exercise group is
at higher risk is debatable but needs consideration and
so will be carefully monitored. The following data will
be collected and recorded in the Participant Diary:
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 A fall in the home: during active delivery of the
home-based rehabilitation programme that does
not meet the criteria of a SAE as above
 A fall in the home: at any time outside of the
delivery of the home-based rehabilitation
programme
 A fall in the garden at home
 A fall at any other location/outside of the home
environment
Falls which are assessed as being related to the study
intervention and are categorised as serious according to
the listed definitions for a serious adverse event, will also
be recorded and reported to the trial office using an SAE
Form.
Other foreseeable adverse events: some adverse
events will be expected as part of the surgery received
rather than inclusion in the CORKA study/receiving
rehabilitation. These will be collected as part of stand-
ard data collection on the study questionnaires/Case
Report Forms (CRFs) but are not classified as report-
able SAEs:
 Infection of knee replacement
 Fracture
 Venous thromboembolism/pulmonary embolism
The trials office will be responsible for reporting all
study SAEs occurring to a participant to the Research
Ethics Committee (REC), which gave a favourable opinion
of the study, where the event is confirmed as ‘serious’,
‘related’ and ‘unexpected’. The information provided to
the REC will be unblinded and will be reported within
15 days of the trial office being made aware.
Quality monitoring
The trial will be conducted according to the Standard
Operating Procedures (SOPs) of the OCTRU. There
will be standardised initial training to all CORKA trial
assessors and clinical staff involved in delivering the in-
terventions at all sites. After the training the following
procedures will be used to promote consistency and
high-quality trial procedures across all sites:
 A member of the CORKA team will observe each
assessor perform at least one of their assessments
to ensure that they take place as per protocol.
Repeat visits will be undertaken should any concerns
arise until reliable and valid assessments occur
 Within 2 weeks copies of all assessment forms will
be sent to the trial office for review in order to
identify any issues concerning missing data or poorly
completed forms. Any issues or concerns will
be discussed with individual assessors
 A member of the CORKA team will check each
site’s trial master file and meet with researchers
and clinicians from each site on an annual basis
(or more frequently should this be necessary)
Intervention compliance
Compliance with the test intervention will be defined as
fulfilling at least four treatment sessions. The number of
physiotherapy visits and the content of the treatment
sessions will be recorded using clinician-completed
treatment logs and patient exercise and participation
diaries. A member of the CORKA team will observe
clinical staff perform one of their treatments to ensure
that all treatments adhere to the protocol. Clinical staff
will be asked to complete a treatment log for each at-
tendance, providing an approximate estimation of the
time spent on key intervention components and detail-
ing and explaining any deviations from the protocol.
Clinician compliance to the treatment protocol will be
assessed and monitored by analysis of the treatment logs
and site monitoring visits.
Retention of participants
The study has two follow-up time points, at 6 and
12 months post randomisation. Follow-up can take place
at the participant’s own home or at the hospital, depend-
ing on where the baseline took place, i.e. the location is
consistent at participant level. Local site staff will organ-
ise the follow-up and liaise directly with the participant
to organise the follow-up visits. Once confirmed, an
appointment reminder letter or email can be sent out to
the participants with the appropriate questionnaire.
An intention-to-treat analysis will be carried out;
therefore, all participants remain in the study irre-
spective of whether they receive or continue with their
allocated treatment (unless the participants themselves
withdraw consent).
Health economics
Health economics analysis will compare the cost-
effectiveness over 1 year of providing the community-
based intervention against standard care. The economic
evaluation will take the form of a cost-utility analysis
from a societal perspective and quality-adjusted life
years (QALYs) will be used as the main health outcome
measure. A micro-costing approach will be used to cal-
culate costs of the home-based rehabilitation interven-
tion and data will be collected from each trial
participant on NHS and social care contacts up to
12 months through the use of a Participant Diary.
Assessments of the health-related quality of life
(HRQoL) of participants in each arm of the trial will be
conducted using the EQ-5D-5L instrument at baseline,
6 and 12 months. Utility values derived from the EQ-
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5D-5L data will be combined with patient survival data
and used to estimate QALYs for each patient up to
12 months.
Mean (standard deviation) costs and QALYs per
patient will be estimated for each arm of the trial. The
difference (95 % confidence interval (CI)) in mean costs
and QALYs between trial arms will be estimated and, if
necessary, an incremental cost-effectiveness ratio (ICER)
calculated to determine the additional cost of generating
one additional QALY. Results will be presented from
an NHS, patient and societal (including informal care)
perspective as recommended by current guidance.
Cost-effectiveness acceptability curves will be used to
determine the probability that the home rehabilitation
programme is cost-effective at different values of
society’s willingness to pay per QALY.
Qualitative study
The nested qualitative study will provide a picture of the
issues facing people with an expected poorer outcome
after KA – particularly around expectations of outcome
rehabilitation and outcomes on the level of function,
activity and participation.
The qualitative study will take place in selected sites
for a small number of participants (approximately 15
participants, in addition to approximately 15 members
of staff ). This number of participants is consistent with
qualitative methodology. There will be a separate con-
sent process before the interviews are carried out.
Recruitment will take place throughout the study to en-
sure a spread of participants that is representative of the
recruited population. Purposive sampling will be used to
achieve a sample of participants which includes: female
and male participants, those with differing levels of func-
tion and disability selected using their baseline LLFDI
score and patients of varying activity levels. In addition,
a sample of clinical staff who have delivered the inter-
vention from differing professional backgrounds, physio-
therapists, occupational therapists and rehabilitation
assistants, will be interviewed.
Participants will be invited to take part in in-depth
semistructured interviews following the intervention.
Interviews will be held at a convenient time and location
for each participant, from previous experience this is
most likely to be at participant’s homes. The develop-
ment of the interview schedule will be iterative and the
questions asked may develop and change as the inter-
views are conducted. The interviews will be digitally re-
corded and fully transcribed. Field notes and memos will
be recorded using a digital notepad. Audio recordings
will be transcribed verbatim and coded. Interview data
will be analysed using Smith’s experiential approach of
Interpretative Phenomenological Analysis [41]. NVivo
software will be used to assist in managing and
presenting the findings. Participants will be offered the
opportunity to view a summary of their results, provid-
ing an opportunity for them to contribute any additional
comments. The research team will discuss the develop-
ment of themes as the research progresses with the aim
of providing different perspectives and enhancing the
development of the themes.
Data and statistical analysis
Sample size
Since the LLFDI has not been used widely there is cur-
rently little information from the existing literature
about the value for the minimal clinically important dif-
ference or about the likely treatment difference in LLFDI
component scores for this type of study. Therefore, our
sample size calculation is based on a moderately small
standardised effect size of 0.275, which is a value that we
expect to be clinically important and associated with
small but worthwhile benefits in rehabilitation trials. Six
hundred and twenty participants (310 per arm) are re-
quired to detect a standardised effect size of 0.275 with
90 % power, 5 % (two-sided) significance and allowing
10 % loss to follow-up. This standardised effect size is
equivalent to detecting around a 3-point difference on
the LLFDI between treatment arms assuming a standard
deviation of 10.91. The DMSC will be reviewing this as-
sumption and monitoring the standard deviation.
Fifteen participants were randomised during an internal
pilot study and will be used in the final analysis.
Statistical analysis
The study will be reported according to the Consoli-
dated Standards of Reporting Trials (CONSORT) 2010
Statement utilising the nonpharmacological treatment
interventions and patient-reported outcome extensions
[42, 43].
The principal comparisons will be performed on an
intention-to-treat basis. The results from the trial will be
presented as comparative summary statistics (i.e. differ-
ence in means) with 95 % CIs. The primary outcome will
be analysed using a linear mixed effects method with re-
peated measures, on outcome measurements at 6 and
12 months, adjusting for baseline score and stratifica-
tion/variables. An interaction between time and rando-
mised group will be fitted to allow estimation of
treatment effect at each time point. We will formally
assess the distribution of the change from baseline for
evidence of departure from normality. If necessary,
data will either be transformed or analysed using a
nonparametric equivalent. Similar approaches will be
carried out for other continuous outcomes.
The nature and mechanism for the missing outcomes
will be investigated, though mixed effects models that
implicitly account for data following a missing-at-random
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mechanism. Sensitivity analyses will be carried out to
examine the robustness of the results with different as-
sumptions being made about departures from randomisa-
tion policies and handling of missing data.
A Statistical Analysis Plan (SAP) containing a more
detailed account of the proposed statistical analysis will
be drafted early in the trial and approved by the Inde-
pendent Monitoring Committee for the trial prior to
the primary analysis data lock and prior to the random-
isation data being added to the database. The data ana-
lysis plan will consider in detail the need for baseline
covariate adjustment. Any changes at this time will be
incorporated into the final SAP and signed off as per
current OCTRU Standard Operating Procedures (SOPs).
Any changes/deviations from the original SAP will be
described and justified in the protocol and/or in the final
report, as appropriate.
The trial will be deemed a success based on the pri-
mary outcome of the total LLFDI based on the p value
and if the lower bound of the 95 % CI is greater than 3
points.
Complier-average causal effect (CACE) will be esti-
mated to assess the impact of the intervention compli-
ance on the effect of the interventions.
Timeline
The trial is funded to run over a period of 51 months and
commenced in August 2014. Data analysis, economic ana-
lysis and report writing is expected to take place from
month 45 onwards (May 2018).
Dissemination
The chief investigator will coordinate dissemination of
data from this study. All publications using data from
this study to undertake original analyses will be submit-
ted to the DSMC, TMG and TSC for review before re-
lease. The final study report will be available on the
HTA website.
We will provide all participants with a summary of the
trial outcome.
Discussion
We have chosen to focus our intervention as a commu-
nity home-based treatment package. We believe this to
be particularly suited to those patients likely to find it
hard to access traditional physiotherapy because of
transport difficulties, social isolation, frailty and low
self-efficacy. For many people relearning daily living
skills within their own home and immediate home en-
vironment is both desirable and essential.
Given the increasing number of KAs, the relative limited
therapy resource available and the increasing age and
frailty of patients receiving joint arthroplasties, it is im-
portant that we concentrate our rehabilitation resources
on those patients who need most help to achieve a good
outcome. Furthermore, it is clear from the existing studies
that current rehabilitation strategies do not meet the
needs of all patients, particularly those who are older and
frailer. Addressing the needs of these patients is particu-
larly crucial because all patients are being discharged
home earlier from the acute setting, meaning that less
time is available for acute physical recovery, rehabilitation
and education; thus, the potential burden of care for these
patients and their families is increased. This is a particular
concern given both the projected increased need for joint
arthroplasty over the next decade to accommodate an age-
ing population and the pressure of potential reductions in
NHS funding.
Trial status
The first patient was randomised to the trial in March
2015. Recruitment for the study is ongoing and currently
stands at 210 at the end of August 2016.
This paper is based upon the latest version of the
protocol v3 November 2015. In addition to this paper,
updated versions of the protocol if amended throughout
the trial will be available on the trial website http://cor-
ka.octru.ox.ac.uk/welcome-corka-trial and will follow
SPIRIT 2013 guidelines [27].
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